Washington, Aug 21 (IANS) Novavax says the US Food and Drug Administration (FDA) has granted expanded emergency use authorisation for its Covid-19 vaccine Adjuvanted for adolescents aged between 12-17 years.
The US company said the vaccine was the first protein-based Covid-19 jab authorised in the US, dpa news agency reported.
Doses of the Adjuvanted are available for use in adolescents upon the Centers for Disease Control and Prevention’s (CDC) recommendation, the company noted.
In July 2022, the FDA had granted emergency use authorisation for a two-dose primary series in adults aged 18 years and older, followed by a recommendation from the CDC Advisory Committee on Immunisation Practices, and endorsement from the CDC.
Disclaimer: Medical Science is an ever evolving field. We strive to keep this page updated. In case you notice any discrepancy in the content, please inform us at [email protected]. You can futher read our Correction Policy here. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website or it’s social media channels. Read our Full Disclaimer Here for further information.
Except for the headline and photo, this story has not been edited by THIP Media staff and is published from a syndicated feed / newswire service.